Healthcare


 CSL Restructure Overshadows Profit Growth Among ASX 200 Companies

CSL Restructure Overshadows Profit Growth Among ASX 200 Companies

August 19, 2025 06:37 PM AEST| By Team Kalkine Media

Highlights,CSL reports stronger earnings performance,Major restructuring with global workforce changes,Seqirus vaccine unit set for demerger,CSL Limited (ASX:CSL), one of the leading,ASX 200 companies,, reported robust annual results, showing growth...

 Pro Medicus (ASX:PME) in Spotlight: Key Metrics Driving ASX 200 Healthcare Tech Growth

Pro Medicus (ASX:PME) in Spotlight: Key Metrics Driving ASX 200 Healthcare Tech Growth

August 19, 2025 05:30 PM AEST| By Team Kalkine Media

Highlights,Pro Medicus (PME) provides advanced radiology IT solutions globally,Strong financial position with consistent revenue and profit growth,Innovative Visage software enhances diagnostic efficiency,Pro Medicus (ASX:PME), a well-known name amon...

 EVE Health Group Moves Closer to Market Launch with First Order for Libbo

EVE Health Group Moves Closer to Market Launch with First Order for Libbo

August 19, 2025 03:54 PM AEST| By Team Kalkine Media

Highlights,EVE Health Group progresses with first order for Libbo.,Treatment aims to provide patient-friendly solution for ED.,Manufacturing underway with launch preparations in motion.,EVE Health Group (ASX:EVE) has taken a significant step forward...

 Argent BioPharma Boosts Pipeline with Strategic Acquisition

Argent BioPharma Boosts Pipeline with Strategic Acquisition

August 19, 2025 03:41 PM AEST| By Team Kalkine Media

Highlights,Argent BioPharma (RGT) to acquire key clinical and IP assets from AusCann (AC8).,Deal adds Neuvis technology, EU manufacturing, and distribution channels.,Integration set to support global expansion and clinical readiness.,Argent BioPharma...

 S&P 200 Lumos Diagnostics and Biotech Advances in Respiratory Care

S&P 200 Lumos Diagnostics and Biotech Advances in Respiratory Care

August 19, 2025 03:22 PM AEST| By Team Kalkine Media

Highlights,Lumos Diagnostics (ASX:LDX) develops FebriDx to distinguish bacterial and viral respiratory infections,Respiratory illnesses remain a leading health burden worldwide with increasing antimicrobial resistance,Biotech sector innovations inclu...

 S&P/ASX 200 CSL Shares Drop as Biotech Flags Job Cuts and Flu Spin-off

S&P/ASX 200 CSL Shares Drop as Biotech Flags Job Cuts and Flu Spin-off

August 19, 2025 02:26 PM AEST| By Team Kalkine Media

Highlights,CSL (ASX:CSL) announces restructuring of influenza vaccine business,Significant workforce reductions are planned alongside the spin-off,ASX 200 faces a downward trend following the company’s updates,The biotechnology sector on the ASX expe...

 S&P 200 Updates CSL Shares Record One-Day Drop Amid Biotech Restructure

S&P 200 Updates CSL Shares Record One-Day Drop Amid Biotech Restructure

August 19, 2025 02:25 PM AEST| By Team Kalkine Media

Highlights,CSL (ASX:CSL) experiences significant decline following corporate restructure and strategic announcements.,BHP (ASX:BHP) signals challenges in the Australian economic landscape impacting outlook.,Reliance Worldwide (ASX:RWC), HMC Capital (...

 ASX 200 Today CSL Shares Face Volatility Amid Mixed Biotech Results

ASX 200 Today CSL Shares Face Volatility Amid Mixed Biotech Results

August 19, 2025 02:14 PM AEST| By Team Kalkine Media

Highlights,CSL (ASX:CSL) reports mixed fiscal year results impacting share performance.,Restructuring plans include staffing reductions and a share buy-back program.,Revenue and underlying EBIT fall short of consensus, while NPATA remains aligned wit...

 Lumos Diagnostics Advances FebriDx with FDA Waiver Application Amid ASX 200 Stocks Momentum

Lumos Diagnostics Advances FebriDx with FDA Waiver Application Amid ASX 200 Stocks Momentum

August 18, 2025 11:05 AM AEST| By Team Kalkine Media

Highlights,Lumos Diagnostics submits CLIA waiver application for FebriDx,Clinical study supports ease of use for broader access,Partnership set to strengthen US market adoption,Lumos Diagnostics (ASX:LDX) has taken a major step forward by submitting...

 Strategic Alliance Brings FebriDx® to the Forefront of U.S. Healthcare

Strategic Alliance Brings FebriDx® to the Forefront of U.S. Healthcare

August 14, 2025 07:52 PM AEST| By Team Kalkine Media

Highlights,Strategic alliance accelerates FebriDx® adoption across U.S. healthcare.,PRO-spectus provides comprehensive support for reimbursement and market access.,Effort aims to improve diagnosis and curb unnecessary antibiotic use.,Lumos Diagnostic...

 ASX200 Pro Medicus (ASX:PME) Records Strong FY2025 Growth and Expands Global Reach

ASX200 Pro Medicus (ASX:PME) Records Strong FY2025 Growth and Expands Global Reach

August 14, 2025 05:56 PM AEST| By Team Kalkine Media

Highlights,Achieved record revenue in FY2025,Strong US market contracts drive performance,Margins reached highest level to date,Pro Medicus posted record-breaking results for FY2025, reinforcing its position as one of the notable performers within th...

 ASX 200 Healthcare Stock Gains Attention in S&P/ASX Indices

ASX 200 Healthcare Stock Gains Attention in S&P/ASX Indices

August 14, 2025 05:04 PM AEST| By Team Kalkine Media

Highlights,Neuren Pharmaceuticals (ASX:NEU) operates in the biotechnology sector with a focus on central nervous system conditions,Lead therapy Daybue, licensed to Acadia (NASDAQ:ACAD), records continued growth in the US market,Preparations underway...

 A Closer Look at Cochlear Ltd (ASX:COH): Key Metrics That Shape Its Valuation

A Closer Look at Cochlear Ltd (ASX:COH): Key Metrics That Shape Its Valuation

August 14, 2025 04:13 PM AEST| By Team Kalkine Media

Highlights,Key metrics offer insight into valuation and performance.,Cochlear Ltd (COH) operates from a strong financial foundation.,Innovation and global demand underpin long-term outlook.,Cochlear Ltd (ASX:COH) is part of the,ASX 200,stocks, reflec...

 ASX 200 Futures Pro Medicus Records Strong Year with Major Global Contracts

ASX 200 Futures Pro Medicus Records Strong Year with Major Global Contracts

August 14, 2025 03:04 PM AEST| By Team Kalkine Media

Highlights,Pro Medicus secures multiple long-term healthcare contracts.,Cloud-native imaging solutions see increased adoption.,Pipeline expands into new medical specialties and AI.,The,ASX 200 Futures,segment has seen notable activity, with Pro Medic...

 Exploring Pro Medicus Ltd (ASX:PME) in the ASX 100 Healthcare Space

Exploring Pro Medicus Ltd (ASX:PME) in the ASX 100 Healthcare Space

August 13, 2025 05:38 PM AEST| By Team Kalkine Media

Highlights,Radiology software solutions supporting global healthcare providers,Consistent revenue streams driven by essential medical services,Expanding role of healthcare technology in diagnostic efficiency,Understanding the PME Landscape,Pro Medicu...

 ASX 200 Orthocell expands Remplir rollout in United States nerve repair sector

ASX 200 Orthocell expands Remplir rollout in United States nerve repair sector

August 13, 2025 04:43 PM AEST| By Team Kalkine Media

Highlights,Orthocell (ASX:OCC) advances Remplir adoption across multiple US hospitals,Value Assessment Committee approvals continue to progress in the US market,Distribution and logistics network strengthened to support expanding demand,ASX 200,liste...

 ASX 200 small caps update: Orthocell expands US presence, Antipa adds expertise, European Lithium advances project

ASX 200 small caps update: Orthocell expands US presence, Antipa adds expertise, European Lithium advances project

August 13, 2025 04:37 PM AEST| By Team Kalkine Media

Highlights,Orthocell (ASX:OCC) strengthens commercial rollout of Remplir in the United States,Antipa Minerals (ASX:AZY) appoints experienced industry professional to its board,European Lithium (ASX:EUR) engages NIRAS for Tanbreez Rare Earth Project D...

 ASX 200 biotechnology company Clarity Pharmaceuticals updates clinical progress

ASX 200 biotechnology company Clarity Pharmaceuticals updates clinical progress

August 13, 2025 04:24 PM AEST| By Team Kalkine Media

Highlights,Clarity Pharmaceuticals (ASX:CU6) secures funding to progress full clinical program,Upcoming therapeutic trial to proceed without external partnership,Upcoming data release expected to differentiate its PSMA imaging agent,ASX 200,listed Cl...

 Orthocell Moves Ahead with Remplir™ Rollout in US Nerve Repair Market

Orthocell Moves Ahead with Remplir™ Rollout in US Nerve Repair Market

August 13, 2025 10:52 AM AEST| By Team Kalkine Media

Highlights,Expansion of Remplir™ adoption in the US market,Strategic VAC approvals progressing across key hospitals,Strengthened logistics and specialist team support in place,Orthocell Ltd (ASX:OCC) is advancing its presence in the US nerve repair m...

 Opyl’s AI Platform Secures Exclusive Role in Clinical Trial Risk Solutions

Opyl’s AI Platform Secures Exclusive Role in Clinical Trial Risk Solutions

August 12, 2025 06:49 PM AEST| By Team Kalkine Media

Highlights,Opyl’s (OPL) TrialKey platform to act as exclusive calculation agent in global biotech insurance products,Partnership provides continuous access to diverse clinical trial data for AI model enhancement,Collaboration targets reducing trial f...

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.